• Explore /
  • Poster
  • / Final analysis of a prospective controlled trial of the efficacy of uracil and tegafur/leucovorin for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201).

Final analysis of a prospective controlled trial of the efficacy of uracil and tegafur/leucovorin for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201).

Abstract Poster

Authors

null

Ken Kondo

Nagoya Medical Center, Nagoya, Japan;

Ken Kondo , Sotaro Sadahiro , Kazuhiro Sakamoto , Takashi Tsuchiya , Takao Takahashi , Hiroki Ohge , Toshihiko Sato , Yukata Ogata , Hideo Baba , Michio Itabashi , Masataka Ikeda , Madoka Hamada , Kiyoshi Maeda , Hiroyuki Masuko , Keiichi Takahashi , Junichi Sakamoto , Mitsuo Kusano , Ichinosuke Hyodo , Masataka Taguri , Satoshi Morita

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

UMIN000007783

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 117)

DOI

10.1200/JCO.2023.41.4_suppl.117

Abstract #

117

Poster Bd #

F14

Abstract Disclosures

Similar Posters

First Author: Megumi Ishiguro

Poster

2022 ASCO Gastrointestinal Cancers Symposium

Changes in prescribing patterns in stage III colon cancer (CC) since the IDEA collaboration.

Changes in prescribing patterns in stage III colon cancer (CC) since the IDEA collaboration.

First Author: Daniel Walden

First Author: Jennifer Leigh Lund

First Author: Naohiro Tomita